Olympus Corporation manufactures and sells precision machineries and instruments worldwide. The company operates through four segments: Medical Business, Scientific Solutions Business, Imaging Business, and Others. It offers endoscopic video endoscopy systems, endoscopic ultrasound systems, ultrasound endoscopes and probes, endoscopic ultrasound observation devices, capsule endoscopy systems, integrated documentation systems, therapeutic equipment, and ancillary products; cleaning, disinfecting, and sterilization systems; gastrointestinal, colono, duodeno, and broncho endoscopes; endoscopy products for gastroenterological surgery, bronchial surgery, urology, gynecology, orthopedic surgery, neurosurgery, and anesthesiology, as well as ear, nose, and throat; and therapeutic and surgical equipment, endoscope ancillary equipment, and endotherapy devices.
Read More…
Industry, Sector and Symbol
Industry Structural clay products
Sub-IndustryN/A
SectorMedical
CIKN/A
Phone813-3340-2111
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$7.21 billion
Profitability
Miscellaneous
Employees35,124
Next Earnings Date2/14/2020 (Estimated)
OptionableNot Optionable
OLYMPUS CORP/S (OTCMKTS:OCPNY) Frequently Asked Questions
What is OLYMPUS CORP/S's stock symbol?
OLYMPUS CORP/S trades on the OTCMKTS under the ticker symbol "OCPNY."
How were OLYMPUS CORP/S's earnings last quarter?
OLYMPUS CORP/S (OTCMKTS:OCPNY) issued its quarterly earnings results on Friday, May, 11th. The company reported $0.24 EPS for the quarter, missing the consensus estimate of $0.32 by $0.08. The company earned $1.98 billion during the quarter, compared to analysts' expectations of $1.97 billion. View OLYMPUS CORP/S's Earnings History.
When is OLYMPUS CORP/S's next earnings date?
What is the consensus analysts' recommendation for OLYMPUS CORP/S?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OLYMPUS CORP/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for OLYMPUS CORP/S.
Has OLYMPUS CORP/S been receiving favorable news coverage?
Media headlines about OCPNY stock have been trending somewhat negative this week, InfoTrie Sentiment Analysis reports. The research group rates the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. OLYMPUS CORP/S earned a daily sentiment score of -1.2 on InfoTrie's scale. They also assigned news coverage about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View News Stories for OLYMPUS CORP/S.
Who are some of OLYMPUS CORP/S's key competitors?
Some companies that are related to OLYMPUS CORP/S include GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Gilead Sciences (GILD), Celgene (CELG), Stryker (SYK), Bayer (BAYRY), Anthem (ANTM), Becton Dickinson and (BDX), Bayer (BAYN), Intuitive Surgical (ISRG), Takeda Pharmaceutical (TAK), Allergan (AGN), Boston Scientific (BSX), Zoetis (ZTS) and Vertex Pharmaceuticals (VRTX).
What other stocks do shareholders of OLYMPUS CORP/S own?
Who are OLYMPUS CORP/S's key executives?
OLYMPUS CORP/S's management team includes the folowing people:
- Mr. Yasuo Takeuchi, Pres, CEO & Director (Age 62)
- Mr. Yasushi Sakai, CFO & Corp. Managing Officer
- Mr. Akihiro Taguchi, COO, Sr. Corp. Managing Exec. Officer & Director (Age 61)
- Mr. Haruo Ogawa, CTO, Sr. Exec. Managing Officer & Director (Age 62)
- Mr. Stefan Kaufmann, Chief Admin. Officer, Corp. Officer (Age 51)
How do I buy shares of OLYMPUS CORP/S?
Shares of OCPNY can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OLYMPUS CORP/S's stock price today?
One share of OCPNY stock can currently be purchased for approximately $15.38.
How big of a company is OLYMPUS CORP/S?
OLYMPUS CORP/S has a market capitalization of $21.00 billion and generates $7.21 billion in revenue each year. The company earns $73.32 million in net income (profit) each year or $0.05 on an earnings per share basis. OLYMPUS CORP/S employs 35,124 workers across the globe.View Additional Information About OLYMPUS CORP/S.
What is OLYMPUS CORP/S's official website?
How can I contact OLYMPUS CORP/S?
OLYMPUS CORP/S's mailing address is SHINJUKU MONOLITH 3-1 NISHI-SHINJUKU 2-CHOME, TOKYO M0, 163-0914. The company can be reached via phone at 813-3340-2111 or via email at [email protected]
MarketBeat Community Rating for OLYMPUS CORP/S (OTCMKTS OCPNY)
MarketBeat's community ratings are surveys of what our community members think about OLYMPUS CORP/S and other stocks. Vote "Outperform" if you believe OCPNY will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OCPNY will underperform the S&P 500 over the long term. You may vote once every thirty days.
